Endothelial Cell Count (ECC) is an important measurement to evaluate corneal endothelial cell health when diagnosing and managing different corneal diseases and assessing safety profiles for ocular procedures. Accurate evaluation requires each single endothelial cell to be identified properly. MERIT provides masked, independent ECC reading, as required in many ocular clinical trials. Learn more: https://lnkd.in/gHY4C4E8 #MERITCRO #YourClinicalEndpointExpert #ophthalmology #clinicalresearch #clinicaltrials #EndothelialCellCount
MERIT CRO
Biotechnology Research
Madison, Wisconsin 6,282 followers
MERIT is a global clinical trial endpoint services provider offering reliable expertise in our therapeutic areas.
About us
MERIT is an innovative clinical endpoint expert providing attentive expertise in our therapeutic areas. We partner with CROs, pharma, and biotech companies to deliver reliable endpoint services in global clinical trials. With the acquisition of OSOD, MERIT now offers preclinical research services, enabling a seamless transition from preclinical to clinical phases of drug development. Together our work advances and accelerates the improvement of therapeutic options for patients worldwide. We have a proven track record providing endpoint expertise to 13 of the top 20 global pharmaceutical companies. We prioritize a collaborative, partnership-driven approach for all projects with scalable solutions and personalized attention. If you’re looking for a partner that will bring dedication and expertise to your clinical trial, consider MERIT.
- Website
-
https://www.meritcro.com/?utm_source=LinkedIn&utm_medium=CompanyPage&utm_campaign=Referral
External link for MERIT CRO
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Madison, Wisconsin
- Type
- Privately Held
- Founded
- 2012
- Specialties
- Ophthalmology clinical trials, corneal endothelial cell count, optical coherence tomography, technician and equipment certification, imaging CRO, Cloud-based imaging platform, Respiratory clinical trials, Contract Research Organization, Respiratory CRO, COPD clinical trials, Asthma clinical trials, AMD clinical trials, Oncology clinical trials, Clinical Endpoint Assessment, and Preclinical Research
Products
![Click here to view EXCELSIOR Imaging Software]()
EXCELSIOR Imaging Software
Picture Archiving & Communication System (PACS) Software
MERIT’s EXCELSIOR technology platform increases accuracy and efficiency by providing a suite of advanced endpoint analysis tools designed based on our extensive collaboration with biopharma companies. With MERIT your study data and images can easily be shared between clinical sites, reading centers, CROs, and Sponsors for maximum transparency. This makes managing global trials involving multiple reading centers and analysis of numerous modalities not only feasible, but practical.
Locations
Employees at MERIT CRO
-
Yijun Huang
CEO at MERIT CRO, Inc.
-
John Laugerman
Director of Engineering - Software Development at Merit CRO
-
Julia Oxley, MBA
Accomplished business professional with extensive experience in leading business development, budgeting, contracting, and operations across multiple…
-
Laura Jacobs
Proposal and Client Solutions Manager
Updates
-
OBN shares encouraging news for non-proliferative diabetic retinopathy (NPDR) patients and Ocular Therapeutix, Inc. The HELIOS-3 #ClinicalTrial of AXPAXLI in NPDR has randomized its first subject. This registrational trial compares 6- and 12-month dosing of AXPAXLI to sham treatment. The study, along with the HELIOS-2 complimentary study, is designed assess whether AXPAXLI could potentially provide durable treatment with less frequent dosing.
🔬 Ocular Therapeutix, Inc. Begins HELIOS-3 Phase 3 Trial for NPDR Ocular Therapeutix has randomized the first patient in HELIOS-3, a Phase 3 registrational trial evaluating AXPAXLI (OTX-TKI) for nonproliferative diabetic retinopathy (NPDR). The trial explores 6- and 12-month dosing and uses a novel ordinal ≥2-step DRSS endpoint to assess treatment impact. 🔗 Read more here: https://lnkd.in/dU5RaYJu #ClinicalTrial #Ophthalmology #DiabeticRetinopathy #NPDR #RetinaResearch #EyeDisease #Innovation #Treatment #AXPAXLI #OcularTherapeutix
-
2026 will be here before you know it! If you’re mapping out next year’s conference travel, let’s connect. We’ll be at events across the country in the coming months - perfect opportunities to network and collaborate. https://lnkd.in/dVGmCNup #MERITCRO #YourClinicalEndpointExpert #clinicaltrials #SCOPEsummit #SCOPE2025 #IO360Summit #GI26 #MaculaSociety
-
-
Equipment certification plays a crucial role in maintaining and improving image quality in #clinicaltrials. Learn how it impacts the overall quality of imaging in our brief info sheet: https://lnkd.in/gBjJykuJ #YourClinicalEndpointExpert #clinicalresearch #imagingsolutions #clinicalresearch #MERITCRO
-
Learn about MERIT’s experience in Wet Age-Related Macular Degeneration (AMD) studies and the associated clinical trial endpoints for this condition in our info sheet. View now: https://lnkd.in/gmJvkgyW #MERITCRO #YourClinicalEndpointExpert #ophthalmology #clinicalresearch #clinicaltrials #AgeRelatedMacularDegeneration #WetAMD
-
🌺 Day 2 in the Aloha State at #SNO2025! Honolulu never disappoints.🌴 ✔️ Matching Hawaiian shirts ✔️ Inspiring Neuro-Oncology discussions ✔️ Poster presentation ✔️ Mid-day painting break ✔️ Stunning island sunsets We're enjoying every moment! Come visit us at booth 207 to start a conversation and snag some cool giveaways. 🦒 MERIT staff: Shinji Yue, MS, MBA, Satej Bhogill, Gene Kim, PharmD, Christopher Sylvia, Alyssa Bartholomew, Jon Loi, PhD Society for NeuroOncology (SNO) 30th Annual Meeting #ClinicalTrials #ClinicalResearch #OncologyTrials #OncologyResearch #MERITCRO #YourClinicalEndpointExpert
-
-
-
-
-
+12
-
-
OBN shared great news for patients with macular edema following RVO! Regeneron Pharmaceuticals has received FDA approval for Eyelea HD (aflibercept injection 8mg) in this indication. Data from the Phase 3 QUASAR #ClinicalTrial of Eylea HD every 8 weeks showed noninferiority in visual acuity gains compared with standard Eylea every 4 weeks. This could represent a significant reduction in treatment burden.
🔬 FDA Approves Eylea HD for Retinal Vein Occlusion (RVO) The FDA has approved Regeneron’s Eylea HD (aflibercept) 8 mg for the treatment of macular edema following RVO, allowing dosing intervals of up to every 8 weeks after initial monthly treatment. The agency also cleared monthly dosing for all Eylea HD indications, including wet AMD, DME, DR, and RVO. 🔗 Read more here: https://lnkd.in/d8YbyKRw #FDA #RetinalVeinOcclusion #Ophthalmology #ClinicalResearch #Retina #EyleaHD
-
Day 1 of #SNO2025 in Honolulu is underway! We invite you to swing by booth 207 and say hello to our #oncology team. MERIT staff in attendance: Shinji Yue, MS, MBA, Satej Bhogill, Gene Kim, PharmD, Christopher Sylvia, Alyssa Bartholomew, Jon Loi, PhD Society for NeuroOncology (SNO) 30th Annual Meeting #ClinicalTrials #ClinicalResearch #OncologyTrials #OncologyResearch #MERITCRO #YourClinicalEndpointExpert
-
-
Curious about what’s new at MERIT? Wondering if you missed any major updates? Our November newsletter has you covered—and you won’t want to skip this one! Inside this month’s edition: ✅ Highlights from our annual corporate strategic meeting in Lake Geneva ✅ Photo recaps from recent conferences in Melbourne, Shanghai, Boston & Chicago ✅ Spotlight on our latest poster presentations ✅ First look at upcoming conferences ✅ Quick roundup of the latest industry news Stay informed. Subscribe now and never miss an update!
-
OBN shared some positive news for Wet AMD patients and EyePoint Pharmaceuticals. Durayvu, the company’s treatment for Wet AMD, is in ongoing Phase III #ClinicalTrials and the independent DSMC recommended that both trials continue as planned. The recommendation indicates that a consistent, favorable safety profile continues to be observed.
🔹 EyePoint Receives Positive DSMC Review for Duravyu Phase 3 Trials EyePoint Pharmaceuticals announced that an independent Data Safety Monitoring Committee (DSMC) has completed its second review of the company’s ongoing phase 3 LUGANO and LUCIA trials evaluating Duravyu for wet AMD. The DSMC recommended that both studies continue as planned with no protocol modifications. Topline data is expected in mid-2026. 🔗 Read more here: https://lnkd.in/dkQgEbn4 #AMD #ClinicalTrial #CompanyNews #EyeHealth #Ophthalmology